RE:RE:RE:RE:UP to 25% of Units Potentially Sold to Insiders We agree to disagree
To summarize your position BSW, if I understand it correctly:
No, you are going to another extreme. The company has some potential and quite a few positives. The way I see it is that the company also has some serious negatives. Aside from the share price continuously going down. I will just name transparency as the most serious one. It's also a weak company overall from capital markets side all the way to sales. Let's not forget that Dialco already has multiple approvals. Where are the sales?
Don't just cherry-pick the good stuff because I can rebuttal that as well.
- "the science is a sham (PMX, EAA, SAMI and DIMI) - they are not inventors
Did they invent these or did they just get rights to sell off the shelf products? - they have no idea what they are doing
Sure, they know how to run a trial but they have their fingers crossed as much as you and I do. Only difference is we don't get paycheques while we all hope for the best. - Kellum was hoodwinked to sign a 2 year contract and leave UofP
What's so special about this guy? Academics are trying to get into private sector all over the place. I'd be more impressed if he was the CSO of (pick a multinational pharmaceutical company) - Toray and Birch Hill were hood-winked
Today has a product they're selling. It's just another market opportunity. I haven't seen them participate in any recent financings. Birch hill has many investments. Baxter was not duped. They took a minuscule chance on a start up. Certainly because it has potential but not because it's guaranteed otherwise it would have been a buyout. - they are completely aligned with shareholders with every financing cuz we're only talking a few million options that will probably expire worthless in 3 years"
Oh .... and "it's all about the "lifestyle" and those invaluable T4 earnings."
Oh...and "they couldn't have pulled off a Athelon or Cytosorb "valuation" with a little bit of effort - cuz the science doesn't measure up."
Oh.."and the sub $ 1 share price prevents any interest - and no one thought of a RS or Nasdaq listing to raise it up"
Do I have that all right?
MM
[/quote]